EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Alcohol Septal Ablation in Hypertrophic Cardiomyopathy: For Which Patients?

Alexandru Achim iD, Adela Mihaela Serban, Stefan Dan Cezar Mot, Gregor Leibundgut, Madalin Marc, Ulrich Sigwart

ESC Heart Failure · 01.06.2023 · 10 (3) · 1570-1579

DOI: 10.1002/ehf2.14272 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift ESC Heart Failure, online erschienen am 13.01.2023. Verfasst von Alexandru Achim und 5 weiteren Autor:innen. Beteiligte Einrichtung: 'Niculae Stancioiu' Heart Institute, University of Medicine and Pharmacy 'Iuliu Hatieganu', Cluj-Napoca, Romania. Hauptthemen laut MEDLINE: Cardiac Surgical Procedures, Cardiomyopathy, Hypertrophic. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Percutaneous and surgical therapies for septal reduction for hypertrophic cardiomyopathy have been going head-to-head for the past 20 years with similar outcomes and mortality rates, although contemporary myectomy seems to materialize its superiority. However, on closer analysis, the external validity of studies advocating myectomy does not translate to all centres. The aim of this review was to examine the most recent data on septal reduction therapy and to attempt to phenotype the appropriate patient for each of the two treatments. The key to similar low mortality rates between ventricular septal myectomy and alcohol septal ablation appears to be proper patient selection performed in high volume clinical environments. Furthermore, we analyse the role of mavacampten (the recently approved cardiac myosin inhibitor) in replacing or complementing the two septal reduction therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiac Surgical ProceduresCardiomyopathy, HypertrophicHumansTreatment OutcomeHeart SeptumCoronary Artery Bypass

Stichwörter der Autor:innen

Alcohol septal ablationHypertrophic cardiomyopathyLeft ventricular outflow tract obstructionMitral valveOutcomesSeptal myectomy

Autor:innen und Institutionen

  • 'Niculae Stancioiu' Heart Institute, University of Medicine and Pharmacy 'Iuliu Hatieganu', Cluj-Napoca, Romania.
  • Klinik für Kardiologie, Medizinische Universitätsklinik, Liestal, Switzerland.
  • University of Geneva, Geneva, Switzerland.

ORCID-Profile: Alexandru Achim

Zitieren

APA

Achim, A., Serban, A. M., Mot, S. D. C., Leibundgut, G., Marc, M., & Sigwart, U. (2023). Alcohol Septal Ablation in Hypertrophic Cardiomyopathy: For Which Patients?. ESC Heart Failure, 10(3), 1570-1579. https://doi.org/10.1002/ehf2.14272

Vancouver

Achim A, Serban AM, Mot SDC, Leibundgut G, Marc M, Sigwart U. Alcohol Septal Ablation in Hypertrophic Cardiomyopathy: For Which Patients?. ESC Heart Failure. 2023;10(3):1570-1579. doi:10.1002/ehf2.14272

BibTeX
@article{Achim2023,
  author = {Achim, Alexandru and Serban, Adela Mihaela and Mot, Stefan Dan Cezar and Leibundgut, Gregor and Marc, Madalin and Sigwart, Ulrich},
  title = {Alcohol Septal Ablation in Hypertrophic Cardiomyopathy: For Which Patients?},
  journal = {ESC Heart Failure},
  year = {2023},
  volume = {10},
  number = {3},
  pages = {1570--1579},
  doi = {10.1002/ehf2.14272}
}
Kostenlos starten →